Literature DB >> 29987005

N6-Furfuryladenine is protective in Huntington's disease models by signaling huntingtin phosphorylation.

Laura E Bowie1, Tamara Maiuri1, Melanie Alpaugh2, Michelle Gabriel3, Nicolas Arbez4, Danny Galleguillos2, Claudia L K Hung1, Shreya Patel1, Jianrun Xia1, Nicholas T Hertz5, Christopher A Ross4, David W Litchfield3, Simonetta Sipione2, Ray Truant6.   

Abstract

The huntingtin N17 domain is a modulator of mutant huntingtin toxicity and is hypophosphorylated in Huntington's disease (HD). We conducted high-content analysis to find compounds that could restore N17 phosphorylation. One lead compound from this screen was N6-furfuryladenine (N6FFA). N6FFA was protective in HD model neurons, and N6FFA treatment of an HD mouse model corrects HD phenotypes and eliminates cortical mutant huntingtin inclusions. We show that N6FFA restores N17 phosphorylation levels by being salvaged to a triphosphate form by adenine phosphoribosyltransferase (APRT) and used as a phosphate donor by casein kinase 2 (CK2). N6FFA is a naturally occurring product of oxidative DNA damage. Phosphorylated huntingtin functionally redistributes and colocalizes with CK2, APRT, and N6FFA DNA adducts at sites of induced DNA damage. We present a model in which this natural product compound is salvaged to provide a triphosphate substrate to signal huntingtin phosphorylation via CK2 during low-ATP stress under conditions of DNA damage, with protective effects in HD model systems.

Entities:  

Keywords:  DNA repair; Huntington’s disease; high-content analysis; neurodegeneration; oxidation

Mesh:

Substances:

Year:  2018        PMID: 29987005      PMCID: PMC6064984          DOI: 10.1073/pnas.1801772115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  74 in total

1.  GTP plus water mimic ATP in the active site of protein kinase CK2.

Authors:  K Niefind; M Pütter; B Guerra; O G Issinger; D Schomburg
Journal:  Nat Struct Biol       Date:  1999-12

Review 2.  Converging pathways in the occurrence of endoplasmic reticulum (ER) stress in Huntington's disease.

Authors:  R Vidal; B Caballero; A Couve; C Hetz
Journal:  Curr Mol Med       Date:  2011-02       Impact factor: 2.222

Review 3.  Energy deficit in Huntington disease: why it matters.

Authors:  Fanny Mochel; Ronald G Haller
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

4.  Kinase inhibitors modulate huntingtin cell localization and toxicity.

Authors:  Randy Singh Atwal; Carly R Desmond; Nicholas Caron; Tamara Maiuri; Jianrun Xia; Simonetta Sipione; Ray Truant
Journal:  Nat Chem Biol       Date:  2011-05-29       Impact factor: 15.040

5.  Kinetin improves IKBKAP mRNA splicing in patients with familial dysautonomia.

Authors:  Felicia B Axelrod; Leonard Liebes; Gabrielle Gold-Von Simson; Sandra Mendoza; James Mull; Maire Leyne; Lucy Norcliffe-Kaufmann; Horacio Kaufmann; Susan A Slaugenhaupt
Journal:  Pediatr Res       Date:  2011-11       Impact factor: 3.756

6.  Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease.

Authors: 
Journal:  Cell       Date:  2015-07-30       Impact factor: 41.582

7.  A huntingtin-mediated fast stress response halting endosomal trafficking is defective in Huntington's disease.

Authors:  Siddharth Nath; Lise N Munsie; Ray Truant
Journal:  Hum Mol Genet       Date:  2014-09-08       Impact factor: 6.150

8.  N17 Modifies mutant Huntingtin nuclear pathogenesis and severity of disease in HD BAC transgenic mice.

Authors:  Xiaofeng Gu; Jeffrey P Cantle; Erin R Greiner; C Y Daniel Lee; Albert M Barth; Fuying Gao; Chang Sin Park; Zhiqiang Zhang; Susana Sandoval-Miller; Richard L Zhang; Marc Diamond; Istvan Mody; Giovanni Coppola; X William Yang
Journal:  Neuron       Date:  2015-02-05       Impact factor: 17.173

9.  ATP increases within the lumen of the endoplasmic reticulum upon intracellular Ca2+ release.

Authors:  Neelanjan Vishnu; Muhammad Jadoon Khan; Felix Karsten; Lukas N Groschner; Markus Waldeck-Weiermair; Rene Rost; Seth Hallström; Hiromi Imamura; Wolfgang F Graier; Roland Malli
Journal:  Mol Biol Cell       Date:  2013-12-04       Impact factor: 3.612

10.  Enhancing mitochondrial proteostasis reduces amyloid-β proteotoxicity.

Authors:  Vincenzo Sorrentino; Mario Romani; Laurent Mouchiroud; John S Beck; Hongbo Zhang; Davide D'Amico; Norman Moullan; Francesca Potenza; Adrien W Schmid; Solène Rietsch; Scott E Counts; Johan Auwerx
Journal:  Nature       Date:  2017-12-06       Impact factor: 49.962

View more
  15 in total

1.  Proteome-Wide Characterizations of N6-Methyl-Adenosine Triphosphate- and N6-Furfuryl-Adenosine Triphosphate-Binding Capabilities of Kinases.

Authors:  Xuejiao Dong; Jianan Sun; Weili Miao; Chia-En A Chang; Yinsheng Wang
Journal:  Anal Chem       Date:  2021-09-22       Impact factor: 8.008

Review 2.  Discovery of Therapeutics Targeting Oxidative Stress in Autosomal Recessive Cerebellar Ataxia: A Systematic Review.

Authors:  Sze Yuen Lew; Michael Weng Lok Phang; Pit Shan Chong; Jaydeep Roy; Chi Him Poon; Wing Shan Yu; Lee Wei Lim; Kah Hui Wong
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-19

3.  CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in huntington's disease.

Authors:  Dahyun Yu; Nicole Zarate; Angel White; De'jah Coates; Wei Tsai; Carmen Nanclares; Francesco Cuccu; Johnny S Yue; Taylor G Brown; Rachel H Mansky; Kevin Jiang; Hyuck Kim; Tessa Nichols-Meade; Sarah N Larson; Katherine Gundry; Ying Zhang; Cristina Tomas-Zapico; Jose J Lucas; Michael Benneyworth; Gülin Öz; Marija Cvetanovic; Alfonso Araque; Rocio Gomez-Pastor
Journal:  Acta Neuropathol Commun       Date:  2022-06-03       Impact factor: 7.578

Review 4.  Protein kinase CK2: a potential therapeutic target for diverse human diseases.

Authors:  Christian Borgo; Claudio D'Amore; Stefania Sarno; Mauro Salvi; Maria Ruzzene
Journal:  Signal Transduct Target Ther       Date:  2021-05-17

Review 5.  How Do Post-Translational Modifications Influence the Pathomechanistic Landscape of Huntington's Disease? A Comprehensive Review.

Authors:  Beata Lontay; Andrea Kiss; László Virág; Krisztina Tar
Journal:  Int J Mol Sci       Date:  2020-06-16       Impact factor: 5.923

Review 6.  Do Post-Translational Modifications Influence Protein Aggregation in Neurodegenerative Diseases: A Systematic Review.

Authors:  Larissa-Nele Schaffert; Wayne G Carter
Journal:  Brain Sci       Date:  2020-04-11

7.  Integrated structural and functional analysis of the protective effects of kinetin against oxidative stress in mammalian cellular systems.

Authors:  Muhammad Naseem; Eman M Othman; Moustafa Fathy; Jibran Iqbal; Fares M Howari; Fatima A AlRemeithi; Geema Kodandaraman; Helga Stopper; Elena Bencurova; Dimitrios Vlachakis; Thomas Dandekar
Journal:  Sci Rep       Date:  2020-08-07       Impact factor: 4.379

8.  A patient-derived cellular model for Huntington's disease reveals phenotypes at clinically relevant CAG lengths.

Authors:  Claudia Lin-Kar Hung; Tamara Maiuri; Laura Erin Bowie; Ryan Gotesman; Susie Son; Mina Falcone; James Victor Giordano; Tammy Gillis; Virginia Mattis; Trevor Lau; Vickie Kwan; Vanessa Wheeler; Jonathan Schertzer; Karun Singh; Ray Truant
Journal:  Mol Biol Cell       Date:  2018-09-26       Impact factor: 4.138

9.  Gene expression profiles complement the analysis of genomic modifiers of the clinical onset of Huntington disease.

Authors:  Galen E B Wright; Nicholas S Caron; Bernard Ng; Lorenzo Casal; William Casazza; Xiaohong Xu; Jolene Ooi; Mahmoud A Pouladi; Sara Mostafavi; Colin J D Ross; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2020-09-29       Impact factor: 6.150

10.  TBK1 phosphorylates mutant Huntingtin and suppresses its aggregation and toxicity in Huntington's disease models.

Authors:  Ramanath Narayana Hegde; Anass Chiki; Lara Petricca; Paola Martufi; Nicolas Arbez; Laurent Mouchiroud; Johan Auwerx; Christian Landles; Gillian P Bates; Malvindar K Singh-Bains; Mike Dragunow; Maurice A Curtis; Richard Lm Faull; Christopher A Ross; Andrea Caricasole; Hilal A Lashuel
Journal:  EMBO J       Date:  2020-08-05       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.